US 11,905,333 B2
Selective immunodepletion of endogenous stem cell niche for engraftment
Irving L. Weissman, Stanford, CA (US); Agnieszka Czechowicz, Menlo Park, CA (US); Deepta Bhattacharya, San Francisco, CA (US); and Daniel Kraft, Portola Valley, CA (US)
Assigned to The Board of Trustees of the Leland Stanford Junior University, Stanford, CA (US)
Filed by The Board of Trustees of the Leland Stanford Junior University, Stanford, CA (US)
Filed on Dec. 22, 2022, as Appl. No. 18/087,618.
Application 18/087,618 is a continuation of application No. 16/035,187, filed on Jul. 13, 2018.
Application 16/035,187 is a continuation of application No. 15/211,679, filed on Jul. 15, 2016, granted, now 10,072,091, issued on Sep. 11, 2018.
Application 15/211,679 is a continuation of application No. 12/447,634, abandoned, previously published as PCT/US2007/083529, filed on Nov. 2, 2007.
Claims priority of provisional application 60/856,435, filed on Nov. 3, 2006.
Prior Publication US 2023/0128340 A1, Apr. 27, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 16/28 (2006.01); A61K 35/28 (2015.01); A61K 39/395 (2006.01); C07K 16/32 (2006.01); A61K 39/00 (2006.01)
CPC C07K 16/2896 (2013.01) [A61K 35/28 (2013.01); A61K 39/3955 (2013.01); C07K 16/2803 (2013.01); C07K 16/2812 (2013.01); C07K 16/2815 (2013.01); C07K 16/2866 (2013.01); C07K 16/32 (2013.01); A61K 2039/505 (2013.01); A61K 2039/54 (2013.01); C07K 2317/73 (2013.01); C07K 2317/76 (2013.01)] 20 Claims
 
1. A method of hematopoietic stem cell engraftment in a human subject, the method comprising:
(i) an ablative treatment to ablate endogenous hematopietic stem cells, comprising systemically administering to the subject a monoclonal antibody that specifically binds to human c-Kit at a dose effective to selectively ablate at least 20% of endogenous stem cells in the bone marrow of the subject, in the absence of radiation or chemotherapy;
(ii) a wash-out period of at least 7 days following administration of the monoclonal antibody that specifically binds to human c-Kit; and
(iii) transplantation of exogenous hematopoietic stem cells into the subject in a dose effective to achieve long term multilineage peripheral blood chimerism, wherein the transplantation is performed prior to 16 days following the administration of the monoclonal antibody that specifically binds to human c-Kit.